What happened

Shares of Bionano Genomics (NASDAQ:BNGO) had skyrocketed 19.3% as of 11:05 a.m. EDT on Friday. The big gain came after the company announced its first-quarter results following the market close on Thursday. 

So what

Bionano's revenue in the first quarter soared 179% year over year to $3.2 million. The consensus analysts' estimate was for revenue of $2.9 million. The company posted a net loss of $9.9 million, but this reflected solid improvement from the net loss of $10.5 million in the prior-year period.

Hand held out with an image of DNA over it

Image source: Getty Images.

The primary key to Bionano's first-quarter success was increased demand for its reagent rental program and consumables. The company sold more flow cells and analyzed more samples in the first quarter than ever before. It also shipped 11 Saphyr genomic mapping systems, up from five in the prior-year period.

Now what

Bionano hopes to increase its installed base to around 150 Saphyr systems by the end of 2021. The life sciences stock could keep its momentum going if significant progress is made toward this goal.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.